 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 GLOBE NEWSWIRE -- Applied Genetic Technologies Corporation Nasdaq: AGTC, a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus AAV-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases IRDs, today announced that it will report financial results for the quarter ended December 31, 2021 before the market opens on Monday, February 14, 2022. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update. 